Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722206 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Addressing Pharma’s R&D Productivity Crisis: Technological and Strategic Initiatives to Improve Core Drug Discovery Capabilities
Datamonitor, April 2004, Pages: 208


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Introduction

External pressures make it difficult to maintain the growth enjoyed by the pharmaceutical industry over the past two decades. Expenditure on R&D is increasing but is not accompanied by corresponding growth in the number of new drugs reaching the market. Companies must fundamentally review R&D business models and exploit new strategies for re-establishing core drug discovery expertise


Scope

Analysis of the R&D challenges faced by leading pharmaceutical companies and critical review of company initiatives to restore productivity


Examines technological opportunities including genomics-oriented target validation, rationalized HTS and GRID computing


Drug discovery database - more than 450 drug discovery deals (Sep 02 - Mar 04) between more than 200 capability providers and 140 pharma companies


Clinical pipeline database - 1,377 projects from the pipelines of 200 companies


Report Highlights

To restore shareholder and stakeholder confidence companies must deliver improved productivity and innovation – they must fundamentally review R&D business models and exploit new strategies for improving core drug discovery expertise.


Investment in technology in the 1990s has not been followed by an increase in R&D productivity. Recognizing that no single technology offers a panacea for drug discovery, the industry must now improve the way in which it evaluates new technologies and capabilities.


The industry can expect the new drug discovery paradigm to be based upon the integration of fields, such as, genomics and proteomics, structural biology, chemistry, physiology, pharmacology and population biology, alongside the integration of the clinic and the laboratory.


Reasons to Purchase

Review the current R&D pipelines and recent drug discovery deal activity of leading the pharmaceutical companies


Analyze competitor deal-making activity and identify emerging trends in drug discovery by examining Datamonitor’s drug discovery deal database


Identify potential drug discovery partners and new opportunities for accessing drug discovery capability




Customers who bought this item also bought

Navigating the Drug Discovery Landscape: A Strategic Overview of Pharmaceutical R&D

Worldwide Drug Discovery R&D

Pharmaceutical Outsourcing in Drug Discovery and Development: Contract Research Opportunity in India

Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery

Bio/Pharma R&D Statistical Sourcebook 2008/2009

Overview of the European Drug Discovery Market

New Approaches to Pharma R&D: Evolving Strategies to Rejuvenate R&D Efficiency

IT Software Tools for Life Science and Drug Discovery R&D

IT Software Tools for Life Science and Drug Discovery R&D

Targeting Kinases for Drug Discovery

Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery

Allergy Drug Pipeline and R&D 2009



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds